ADAR1 Capital Management »

Nextcure shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Nextcure (NXTC) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Nextcure

Tip: Access up to 7 years of quarterly data

All positions including Nextcure held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nextcure by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $96k 43k 2.23
2023-12-31 $69k 60k 1.14

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Nextcure

Sofinnova Ventures
Logos Global Management
Affinity Asset Advisors
OrbiMed Advisors
Vanguard Group
BlackRock
BlackRock
Tang Capital Management
Cable Car Capital
Long Focus Capital Management
Acadian Asset Management
Renaissance Technologies
Acuitas Investments
Federated Investors
BML Capital Management

View all funds holding Nextcure